UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report: March 8, 2017
(Date of earliest event reported)
ANAPTYSBIO, INC.
(Exact Name of Registrant as Specified in Its Charter)
| Delaware | 001-37985 | 20-3828755 | ||
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
10421 Pacific Center Court, Suite 200 San Diego, CA | 92121 | |
| (Address of Principal Executive Offices) | (Zip Code) |
(858)362-6295
(Registrant’s Telephone Number, Including Area Code)
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if theForm 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant toRule 14a-12 under the Exchange Act (17 CFR240.14a-12) |
| ☐ | Pre-commencement communications pursuant toRule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant toRule 13e-4(c) under the Exchange Act (17 CFR240.13e-4(c)) |
Item 2.02 Results of Operations and Financial Condition.
On March 8, 2017, AnaptysBio, Inc. (“AnaptysBio”) issued a press release announcing its financial results for the year ended December 31, 2016. A copy of the press release is attached as Exhibit 99.01 to this Current Report onForm 8-K.
The information in this Item 2.02, including Exhibit 99.01 to this Current Report on Form8-K, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the accompanying Exhibit 99.01 shall not be incorporated by reference into any registration statement or other document filed by AnaptysBio with the Securities and Exchange Commission, whether made before or after the date of this Current Report on Form8-K, regardless of any general incorporation language in such filing (or any reference to this Current Report on Form8-K generally), except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
| (d) Exhibits. | ||
| 99.01 | Press release issued by AnaptysBio regarding its financial results for the year ended December 31, 2016, dated March 8, 2017. | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
AnaptysBio, Inc. | ||||||
Date: March 8, 2017 | By: | /s/ Dominic Piscitelli | ||||
Name: Dominic Piscitelli | ||||||
Title: Chief Financial Officer | ||||||
EXHIBIT INDEX
Number | Description | |
| 99.01 | Press release issued by AnaptysBio regarding its financial results for the year ended December 31, 2016, dated March 8, 2017. | |
